Abstract
Introduction

Acute leukemias (ALs) are broadly classified as having a myeloid or T/B-lymphoid lineage based on the expression of surface or cytoplasmic antigens of proliferating blasts, as well as on morphological features. In addition to these classes, there is a rare type of acute leukemia that is difficult to classify, and which concurrently has morphologic, cytochemical and immunophenotypic characteristics of both myeloid and T-or B-lymphoid lineages. The recent WHO classification refers to this type of entity as bilineage AL, or biphenotypic AL (BAL), and places it into a subtype of the group 'acute leukemia of ambiguous lineage' (1, 2). Bilineage AL is defined by the detection of two separate blast populations, with each population expressing markers of a distinct lineage. In contrast, BAL is characterized by one blast population that co-expresses B-lymphoid and myeloid markers, or, less frequently, T-lymphoid and myeloid markers. The relationship between bilineage AL
and BAL is not completely clear (1, 2 (3, 4, 6 (3, 4, 7) . It is generally believed that BAL is derived from multipotent stem cells in bone marrow that can express antigens from more than one cell line (4) . Therefore, most cases of BAL show expression of early hemopoietic stem cell markers such as CD34 (3, 4) .
Since knowledge about BAL is limited, it was not possible to deduce with certainty its origin or etiology in our patient. It is also unclear, both in terms of clinical and biological presentation and also with regard to treatment outcome, (Figs. 2A, 2B) .
t wi t h F I T C ( f l u o r e s c e i n ) a n d P E ( p h y c o e r y t h r i n ) c o n j u g a t e d mo n oc l o n a l a n t i b o d i e s . Nu c l e a r a n d c y t o p l a s mi c s t a i n i n g wa s c a r r i e d o u t b y f l o w c y t o me t r y a f t e r f i x at i o n a n d p e r me a b i l i z a t i o n o f t h e c e l l s . A) T h e my e l o i d a s s o c i a t e d a n t i g e n s CD3 3 , CD6 5 , CD1 1 7 , a n d MP O we r e p o s i t i v e . CD3 4 wa s n e g a t i v e . B ) T -l y mp h o i d a s s o c i a t e d ma r k e r s CD2 , CD3 ( CD3 c y t ) a n d CD7 we r e e x p r e s s e d . T d T a n d CD3 4 we r e n o t e x p r e s s e d . C) T h e e x p r e s s i o n o f c e rt a i n B -l y mp h o i d ma r k e r s ( CD7 9 a , CD1 9 , CD2 0 a n d I g M) a r e n e g a t i v e . D) 2 0 . 2 % o f b l a s t c e l l s e xp r e s s e d CD3 c y t . negative for terminal deoxynucleotidyl transferase (TdT) and for CD34 antigen
To treat BAL, the patient received a conventional induction chemotherapy regimen designed for AML [cytarabine (Ara-C: 100 mg/m 2 /day at 1-7 days), idarubicin (IDR: 12 mg/m 2 /day at 1-3 days)]. He responded well to this treatment, which resulted in a complete remission (CR).
Discussion
We (3, 8, 9) .
Biphenotypic leukemia is diagnosed when the score is 2 or more for the myeloid lineages and 2 or more for one of the T-lymphoid lineages (8). According to this system, our patient's score was 5 for the myeloid lineage and 3.5 for the lymphoid lineages. At this time, there are no generally accepted treatment protocols for patients with BAL. Rubio et al (10), in a series of seven cases of BAL with T-lymphoid and myeloid markers (T-BAL) who received a chemotherapy designed for ALL consisting of cyclophosphamide, vincristine, prednisone and either daunorubicin or idarubicin as induction therapy, reported that 5 of 7 patients could not achieve CR, but all of them were in CR after salvage therapy (mitoxantrone plus high-dose Ara-C) as used in AML (10). On the other hand, Aribi et al reported that 80% of T-BAL patients treated as the first therapy with regimens devised for treating ALL (HCVAD [high-dose cyclophosphamide, vincristine, adriamycin and dexamethasone]) entered CR (6).
We therefore emphasize that in order to chose the appropriate therapy and better understand the biological basis of BAL, it will be necessary to elucidate the nature or origin of the neoplastic cells. In the present case, FACS analysis showed positivity of the blast cells for MPO antigen. Expression of the myeloid markers CD33 and CD13 is reported to correlate with peroxidase activity (11) (13, 14) . 
